Increase your knowledge about Multiple Myeloma, the disease itself and treatment protocols. Is Cure possible. Are we there? Data from Multiple Myeloma clinical trials leading to individualized treatment protocol for every patient, aiming for longer remissions and turning remissions into cure.
Familiarize yourself on common chemotherapy protocols and novel agents being used around the globe for treatment of Multiple Myeloma. Have a Question about Multiple Myeloma and current clinical trials, Submit your question here. Read our FAQ section to learn answers to most frequently asked questions about Multiple Myeloma treatment. In this case, observation may be sufficient. Ixazomib may stop the growth of cancer by interfering with proteasomes the protein breakdown mechanism in the cells.
Pomalidomide and dexamethasone can modify and regulate the immune system and may stop cancer cells from growing. The purpose of the phase 1 portion of this research study is to find out more about the side effects of belantamab and what doses of belantamab are safe for people when combined with lenalidomide and daratumumab, and to find the right dose for the phase 2 portion of the trial. This trial is exploring the use of a new drug called belantamab to be used in combination with daratumumab and lenalidomide and not using the same doses of dexamethasone as has been done with previous combinations.
This randomized phase II trial compares how well two different doses of carfilzomib work when given with dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement or has not responded to treatment. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib together with dexamethasone may kill more cancer The primary purpose of this study is to evaluate the safety and effectiveness of TAK in combination with anti-CD38 monoclonal antibodies.
TAK is being tested in combination with anti-CD38 monoclonal antibodies to treat participants who have relapsed or refractory multiple myeloma. The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant in an effort to help prolong the amount of time the participants are disease-free after transplant.
IRD is a three-drug regimen consisting of ixazomib, lenalidomide also called Revlimid , and dexamethasone. After 4 cycles of IRD, the participants will be randomized to receive maintenance therapy either with ixazomib or lenalidomide.
This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Giving bortezomib or carfilzomib together with lenalidomide and dexamethasone may kill more cancer cells. This phase II trial studies how well ixazomib citrate, pomalidomide, dexamethasone, and stem cell transplantation works in treating patients with multiple myeloma that has come back or does not respond to treatment. Giving chemotherapy, such as pomalidomide and dexamethasone, before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient?
After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving ibrutinib, lenalidomide, and dexamethasone may work better in The purpose of this study is to evaluate selinexor combined with carfilzomib, pomalidomide and dexamethasone or pomalidomide and dexamethasone for the treatment of relapsed refractory multiple myeloma. A challenge in CAR T-cell development is to generate a product that consistently expands, persists, and mediates durable antitumor responses after infusion.
Multiple preclinical and translational studies have suggested that the differentiation state of adoptively transferred T cells can influence the ability of these cells to persist and promote durable antitumor immunity.
Less differentiated T cells have shown an increased ability to proliferate, persist, and mediate responses in mouse tumor models compared to more differentiated effector memory cell subsets in certain studies.
This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma SMM.
Subjects will receive treatment in 3 phases - induction 6 cycles , consolidation 6 cycles , and maintenance 12 cycles. Each cycle is 28 days. Does idasanutlin in combination with ixazomib and dexamethasone contribute to better outcomes for patients with multiple myeloma who have been previously treated for their disease?
This phase II trial studies how well lenalidomide and dexamethasone work in treating patients with relapsed or refractory multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Giving lenalidomide together with dexamethasone may kill more cancer cells. This phase II trial studies how well pomalidomide, ixazomib citrate, and dexamethasone work in treating patients with previously treated multiple myeloma or plasma cell leukemia.
Biological therapies, such as pomalidomide, and dexamethasone, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Giving pomalidomide, ixazomib citrate, and dexamethasone together may be more effective in treating multiple myeloma. The purpose of this study is to determine the effectiveness and safety of bb in subjects with relapsed and refractory MM Cohort 1 and in subjects with HR MM having progressed within one year of initial treatment Cohort 2.
Approximately subjects will be enrolled into one of two cohorts. The cohorts will start in The primary purpose of this study is to determine if bortezomib, daratumumab, lenalidomide and dexamethasone Btz-DRd consolidation followed by daratumumab and lenalidomide DR maintenance after standard induction therapy with daratumumab, lenalidomide and dexamethasone DRd results in superior overall survival compared to DRd consolidation followed by DR maintenance, in MRD positive patients.
The purpose of this study is to compare the effectiveness rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria of daratumumab subcutaneous Dara-SC in combination with carfilzomib and dexamethasone Kd with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously exposed to daratumumab intravenous Dara-IV to evaluate daratumumab retreatment.
Primary Objective: To demonstrate the benefit of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival PFS as compared to pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma MM.
The purpose of this study is to determine the safety of TAS and determine the most appropriate dose for the subsequent phase 2 safety and efficacy study in patients with advanced solid tumors and multiple myeloma with genetic abnormalities. The progression of cancers is caused by a complex series of multiple genetic and molecular events leading to changes in the patients DNA.
However, FGFR gene abnormalities have been linked to various cancers. TAS is a highly potent, selective small molecule inhibitor This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with relapsed multiple myeloma.
Dinaciclib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving dinaciclib and bortezomib together with dexamethasone may kill more cancer cells. Phase Ib, open-label study to evaluate the safety, tolerability, pharmacokinetics PK , pharmacodynamics PD and clinical activity of GSK dosed in combination with bortezomib and dexamethasone in multiple myeloma MM subjects who have failed at least one line of systemic treatment.
Part 1 will identify the maximum tolerated dose s MTD of the combination regimen. Schedule A - GSK administered once daily with bortezomib 1. Part 2 will further explore the safety, tolerability and clinical activity of the MTD s identified in Part 1, including a pharmacokinetic cohort. The purpose of this study is to assess the side effects and best dose of R- - -gossypol acetic acid when given together with lenalidomide and dexamethasone, and to see how well it works in treating patients with multiple myeloma that has come back after a period of improvement or has gotten worse after treatment.
Biological therapies, such as lenalidomide and anakinra, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. It is not yet known whether lenalidomide and dexamethasone are more effective with The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone DRd to that of lenalidomide and dexamethasone Rd , in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.
The purpose of the study is to compare once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent IMiD. RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Thalidomide may stop the growth of cancer cells by blocking blood flow to the tumor. Giving combination chemotherapy together with carfilzomib and thalidomide may kill more cancer cells. This phase II trial studies how well erismodegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma. Erismodegib and lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may delay the recurrence of myeloma after a stem cell transplant.
The primary objective of the study is to determine the safety and tolerability of ICLR, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor.
This research is being done to find out if altering the immune system by giving Prevnar vaccine, Tadalafil, and activated marrow infiltrating lymphocytes MILs can improve outcomes for multiple myeloma patients who receive a standard autologous stem cell transplant.
The study will consist of an escalating dose-escalation portion Part 1 as well as an expansion of each cohort ie, Cohort C: Monotherapy MonoT and Cohort D: Combination treatment with 2 drugs DoubleT at the recommended Phase 2 dose RP2D to further evaluate safety and estimate preliminary efficacy Part 2.
The purpose of this study is to assess the effects of administration of daratumumab when combined with VELCADE bortezomib and dexamethasone compared with bortezomib and dexamethasone alone, for participants with relapsed or refractory multiple myeloma. This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment.
Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving selinexor, carfilzomib, and dexamethasone may be a better treatment for This phase II trial studies how well ixazomib citrate, lenalidomide, dexamethasone, and daratumumab work in treating patients with newly diagnosed multiple myeloma.
Monoclonal antibodies, such as daratumumab, may block cancer growth in different ways by targeting certain cells. Giving ixazomib citrate, lenalidomide, dexamethasone, and daratumumab Renal impairment is a major complication of multiple myeloma MM and majority of MM participants either are at risk or already have renal dysfunction at initial diagnosis.
The purpose of this study is to show how well lenalidomide and dexamethasone work with or without daratumumab in treating patients with high-risk smoldering myeloma. Clinical trials are conducted worldwide under rigorous guidelines to help doctors find out whether new cancer treatments are safe and effective or better than the standard treatment.
Drugs and Drug Combinations. Recent advances in myeloma treatment have resulted in improved treatment responses and overall survival rates in both newly diagnosed and relapsed cases of myeloma. Eventually, however, nearly all patients will experience a relapse of the disease because, with time, myeloma cells become resistant to current drug therapies.
This means there is a continuing role for the introduction of investigational agents that overcome drug resistance. Several new approaches, including combination therapies to counteract drug resistance, are being studied in clinical trials for myeloma treatment. Various forms of immunotherapy are being studied in clinical studies, including:.
Proteasome Inhibitors PIs. These drugs block proteasome activity, leading to cancer cell death. Several studies are examining the efficacy and safety of PIs, in combination with other agents, for the treatment of newly diagnosed and also relapsed and refractory cases of myeloma.
Stem Cell Transplantation.
0コメント